MetaMelNiche · Deciphering the melanoma-niche cell interplay to identify novel treatments for metastatic melanoma
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2023-09-01 → 2025-08-31
- EU contribution
- €206,365
- Participants
- 2
- Scheme
- HORIZON-TMA-MSCA-PF-EF
Lines connect the coordinator with its partners.
Results in brief
Deciphering the melanoma-niche cell interplay to identify novel treatments for metastatic melanoma
Problem to be addressed: The overarching aim of MetaMelNiche is to define the impact of signals from the cancer cell niche on melanoma dissemination in vivo, with the long-term goal of discovering drug targets and developing new pharmacologic strategies against metastatic melanoma. The influence of the cancer cell niche on cancer cell adhesion and migration has only recently become a subject of investigation, and in non-epithelial tumours like melanoma, that do not arise from well-structured organs, these mechanisms remain largely obscure. Previous research has mostly focused on cell-intrinsic properties of cancer cells, whilst the impact of signals from the cancer cell niche on melanoma dissemination in vivo and in melanoma patients has been largely unexplored. MetaMelNiche, for the first time, fills this gap: I have used state-of-the-art techniques to define the impact of signals from the cancer cell niche on melanoma dissemination in vivo, with the long-term goal of discovering drug targets and developing new pharmacologic strategies against metastatic melanoma. Why is it important for society? Despite significant progress in the treatment and management of patients with cancer, metastatic tumours remain hard to treat and highly lethal. In the case of melanoma, the most aggressive form of skin cancer, the 5-year survival rate drops from almost 100% for localized tumours that can be removed by surgery to only 50% in the presence of metastases, despite the effectiveness of immunotherapies and targeted therapies. MetaMelNiche will generate invaluable insights into the mechanisms by which signals from the cancer cell niche impact the dissemination capacity of melanoma cells and may provide new opportunities for therapeutic intervention against metastatic tumours. What are the objectives? 1) Elucidate and target the mechanism by which IGF1 modulates adherens junction formation and cell migration in melanoma through pathway analyses in human melanoma cell lines and genetic and pharmacologic manipulation in zebrafish models. 2) Identify and study interactions between melanoma cells and their niche by scRNA-seq analysis followed by modelling in zebrafish and in human reconstructed skin coupled with advanced live-cell imaging.
Data: CORDIS, © European Union
Project objective
Metastasis is the leading cause of death among patients with solid tumours including melanoma, the most serious type of skin cancer. Despite tremendous progress in the development of effective targeted and immunotherapies, patient survival is still low. Understanding the mechanisms regulating the dissemination of cancer cells is critical to uncover new vulnerabilities of aggressive tumours. Whilst previous research has mostly focused on cell-intrinsic properties of cancer cells, the aim of this project is to define the impact of signals from the cancer cell niche on melanoma dissemination in vivo, with the long-term goal of discovering drug targets and developing new pharmacologic strategies against metastatic melanoma. Building upon previous results from the Ablain laboratory, I will elucidate and target the mechanism by which melanoma cells change their adhesion properties in response to local IGF1 signalling. Additionally, new interactions between melanoma cells and niche cells will be identified by scRNA-seq in human metastatic melanoma tissue obtained from the HCL Hospital, and recapitulated in reconstructed human skin systems and in zebrafish models. I will investigate the role of these interactions in the regulation of melanoma cell behaviour by combining genetic and pharmacologic manipulation with cutting-edge live-imaging in vitro and in vivo. This fellowship, through advanced interdisciplinary and intersectoral training and collaborations, will serve as a launchpad for reaching a position of academic independence, whilst facilitating a transfer of knowledge between myself, the CRCL and several collaborators, and addressing an unmet need for a better understanding of the behaviour of aggressive tumours. I will use this award to expand my skillset, build an international professional network, and establish myself as an expert in the field of cancer cell behaviour, producing high quality, cutting-edge research with strong translational potential.
Original text from CORDIS.
Participants
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisCoordinatorFrance
- THE UNIVERSITY OF EDINBURGH · EdinburghUnited Kingdom
Links
- View on CORDIS
- DOI: 10.3030/101066495
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e509495ebb&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5202f0b3e&appId=PPGMS
Data: CORDIS, © European Union
